

Technology Advisory Committee C Interests Register Topic Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over [ID4024] Publication Date: 15/01/2025


| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|-----------------------|--------------------------------|---------------------------|--|----------------------|--|
| Satish Venkateshan | TAC C Committee Member | Direct- financial | Regeneron is developing therapeutics for a broad range of diseases. Satish Venkateshan works for Regeneron, pharmaceuticals/biotech company. Satish Venkateshan also owns shares in the company and has stock options. | 19/02/2024 | It was agreed that Satish Venkateshan's declaration would not prevent him from participating in discussions on this appraisal |
| Michael Chambers | TAC C Committee Member | Direct- financial | Michael Chambers has provided a small amount of consulting advice indirectly to Santhera (ie to an agency working Santhera) on DMD. Michael Chambers was conflicted and did not attend this discussion. | 22/02/2024 | It was agreed that Michael Chambers' declaration would prevent him from participating in discussions on this appraisal |
| Ian Watson | NICE, Associate Director | Non-financial interest | Ian Watson acted as NICE's representative on the steering group for Project HERCULES, providing advice to the project. | 14/03/2024 | It was agreed that Ian Watson's declaration would not prevent him from participating in discussions on this appraisal |



| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|-------------------|-----------------|-------------------|--|----------------------|---|
| Anne-Marie Childs | Clinical expert | | Anne-Marie Childs has received professional fees for contributing to advisory boards for Roche, Pfizer and PTC therapeutics in the last 12 months. | 01/09/2023 | It was agreed that Anne- Marie Childs' declaration would not prevent her from providing expert advice to the committee. |
| | | Direct- financial | Anne-Marie Childs was the coordinator of the H2020 grant (VISION DMD) for the development of vamorolone for DMD – co-funded by ReveraGen (2017-2022) – no personal fees; funding received through Newcastle University Anne-Marie Childs was the study chiar of the VBP15-004 study (Phase IIb study to evaluate the safety and efficacy of vamorolone in children age 4-7 with DMD- no personal fees; funding received through Newcastle University Anne-Marie Childs was the UK CI and PI of the VBP15-002 and 003 studies – Phase 2 studies to evaluate the safety of vamorolone in 4-7 years old children with DMD; no personal fees; funding received through Newcastle Hospital Trust Anne-Marie Childs received reimbursement from Santhera for attending the World Muscle Society Conference in Saint Malo in 2017 | 04/06/2024 | |



| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|------------------|-----------------|----------------------------|--|----------------------|--|
| | | Direct – non- financial | Anne-Marie Childs has publications on vamorolone together with ReveraGen- no funding of fees received. Santhera has provided funding to Rochester University to access the data from the FOR DMD study, for which Anne-Marie Childs was co-investigator (NIH grant) and study chair – funding through Rochester University, no fees of funding received personally or through Newcastle University | 04/06/2024 | |
| Michela Guglieri | Clinical expert | Direct- financial | Michela Guglieri was the coordinator of the H2020 grant (VISION DMD) for the development of vamorolone for DMD – co-funded by ReveraGen (2017-2022) – no personal fees; funding received through Newcastle University. Michela Guglieri was the study chiar of the VBP15-004 study (Phase Ilb study to evaluate the safety and efficacy of vamorolone in children aged 4-7 with DMD- no personal fees; funding received through Newcastle University. Michela Guglieri was the UK CI and PI of the VBP15-002 and 003 studies – Phase 2 studies to evaluate the safety of vamorolone in | 29/08/2023 | It was agreed that Michela Guglieri's declaration would not prevent her from providing expert advice to the committee. |



| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|------|----------------|----------------------------|--|----------------------|----------|
| | | Direct – non- financial | 4-7 years old children with DMD; no personal fees; funding received through Newcastle Hospital Trust. Michela Guglieri received reimbursement from Santhera for attending the World Muscle Society Conference in Saint Malo in 2017. Michela Guglieri has publications on vamorolone together with ReveraGen- no funding of fees received. Santhera has provided funding to Rochester University to access the data from the FOR DMD study, for which they were coinvestigator (NIH grant) and study chair – funding through Rochester University, no fees of funding received personally or through Newcastle University | | |